The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca Spain; Eisai; Lilly; Novartis; Pfizer; Roche
Research Funding - Eisai; Novartis; Pfizer; Roche/Genentech; Tesaro
Travel, Accommodations, Expenses - Celgene; Lilly; Lilly; Pfizer; Roche
Other Relationship - MedSIR
Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).
 
Maria Cortes
Speakers' Bureau - Roche
 
Alfonso Cortés Salgado
Consulting or Advisory Role - Clovis Oncology; GlaxoSmithKline; Pfizer
Speakers' Bureau - AstraZeneca Spain; GlaxoSmithKline; MSD; Novartis
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca
Other Relationship - ONCARE Madrid
 
Serafin Morales Murillo
No Relationships to Disclose
 
Isabel Blancas
Honoraria - AstraZeneca Spain; Bristol-Myers Squibb; Celgene; Eisai; Kirin Pharmaceuticals; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Veracyte
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; Celgene; Eisai; Kirin Pharmaceuticals; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Veracyte
Research Funding - AstraZeneca Spain (Inst); Lilly (Inst); Roche (Inst)
 
Patricia Cortez
No Relationships to Disclose
 
Isabel Calvo Plaza
No Relationships to Disclose
 
Nieves Diaz Fernandez
No Relationships to Disclose
 
Alejandro Martinez-Bueno
No Relationships to Disclose
 
Manuel Ruiz-Borrego
No Relationships to Disclose
 
Salvador Blanch
No Relationships to Disclose
 
Elisenda Llabres
Consulting or Advisory Role - Ipsen; Pfizer
 
Frederik Marmé
No Relationships to Disclose
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
Valentina Guarneri
Consulting or Advisory Role - Gilead Sciences (I); Lilly; MSD; Novartis; Roche
Speakers' Bureau - Lilly; Novartis
Research Funding - GlaxoSmithKline
Travel, Accommodations, Expenses - Celgene; Tesaro
 
Joseph Gligorov
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Immunomedics; MSD; Novartis; Onxeo; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Genomic Health; Immunomedics; Ipsen; MacroGenics; MSD; Novartis; Onxeo; Pfizer; Roche; Seagen
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Immunomedics; Ipsen; MacroGenics; MSD; Novartis; Onxeo; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genomic Health (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Expert Testimony - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Immunomedics; Ipsen; MacroGenics; MSD; Novartis; Onxeo; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; MSD; Novartis; Pfizer; Roche; Seagen
 
José Manuel Pérez-García
Consulting or Advisory Role - AstraZeneca Spain; Daiichi Sankyo; Eisai; Lilly; Roche; Seagen
Travel, Accommodations, Expenses - Roche
 
Miguel Sampayo-Cordero
Employment - MedSIR
Honoraria - Ability Pharma; MedSIR; optimapharm; Syntax for Science
Consulting or Advisory Role - MedSIR; optimapharm; Syntax for Science
Speakers' Bureau - MedSIR
Research Funding - MedSIR
Travel, Accommodations, Expenses - MedSIR; optimapharm; Roche; Syntax for Science
 
Andrea Malfettone
Employment - MedSIR
 
Antonio Llombart Cussac
No Relationships to Disclose
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche